The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) ~~Benzodiazepine derivative~~ A benzodiazepine compound of formula I:



I

in which

the dashed lines indicate the possible presence of a double bond;

R_1 represents optionally halogenated (C_1-C_{18})alkyl, optionally halogenated (C_1-C_{18})alkoxy, halogen, nitro, hydroxyl or (C_6-C_{18})aryl, which is optionally ~~(optionally~~ substituted with optionally halogenated (C_1-C_{10})alkyl, optionally halogenated (C_1-C_{12})alkoxy, halogen, nitro or hydroxyl ~~hydroxyl)~~;

n represents 0, 1, 2, 3 or 4;

R_2 and R_3 represent, independently of each other, hydrogen; optionally halogenated (C_1-C_{18})alkyl; (C_1-C_{18})alkoxy; (C_6-C_{18})aryl; (C_6-C_{18})aryl(C_1-C_{12})alkyl; heteroaryl; heteroaryl(C_1-C_{12})alkyl; (C_6-C_{18})aryloxy; (C_6-C_{18})aryl(C_1-C_{12})alkoxy; heteroaryloxy; or heteroaryl(C_1-C_{12})alkoxy; in which the aryl and heteroaryl portions of these radicals are optionally substituted with halogen, optionally halogenated (C_1-C_{12})alkoxy, optionally halogenated (C_1-C_{12})alkyl, nitro or ~~and~~ hydroxyl;

~~R_4 represents hydrogen, (C_1-C_{18})alkyl or (C_6-C_{18})aryl, the said aryl group optionally being substituted with halogen, optionally halogenated (C_1-C_{12})alkoxy, optionally halogenated~~

~~(C_1-C_{12})alkyl, nitro or hydroxyl;~~

X represents S, O or -NT in which T represents a hydrogen atom, (C_1-C_{12})alkyl, (C_6-C_{18})aryl, (C_6-C_{18})aryl(C_1-C_{12})alkyl or (C_6-C_{18})arylcarbonyl;

~~R_5 represents (C_1-C_{18})alkyl; hydroxy(C_1-C_{18})alkyl; (C_6-C_{18})aryl(C_1-C_{12})alkyl; (C_3-C_{12})cycloalkyl(C_1-C_{12})alkyl; (C_5-C_{12})cycloalkenyl(C_1-C_{12})alkyl; heteroaryl(C_1-C_{12})alkyl optionally substituted with one or more substituents Su as defined below; (C_3-C_{12})cycloalkyl optionally substituted with oxo and optionally fused to (C_6-C_{18})aryl, the assembly optionally being substituted with one or more substituents Su as defined below; a group $-CH_2-CR_a=CR_bR_c$ (in which R_a, R_b and R_c are chosen, independently, from (C_1-C_{18})alkyl, (C_2-C_{18})alkenyl, hydrogen and (C_6-C_{18})aryl); a group -CHA-CO-Z (in which Z represents optionally halogenated (C_1-C_{18})alkyl; optionally halogenated (C_1-C_{18})alkoxy; (C_3-C_{12})cycloalkyl; (C_3-C_{12})cycloalkyl optionally substituted with oxo and optionally fused to (C_6-C_{18})aryl; (C_6-C_{18})aryl(C_1-C_{18})alkyl; (C_6-C_{18})aryl(C_1-C_{12})alkoxycarbonylamino(C_1-C_{12})alkyl in which alkyl is optionally substituted with (C_1-C_{12})alkoxycarbonyl(C_1-C_{12})alkyl; (C_1-C_{12})alkoxycarbonyl; (C_1-C_{12})alkoxycarbonyl(C_1-C_{12})alkyl; (C_6-C_{10})aryl; (C_6-C_{18})aryl fused to an unsaturated heterocycle optionally substituted with oxo; or heteroaryl;~~

~~the aryl, heterocycle, cycloalkyl and heteroaryl portions of these radicals optionally being substituted with halogen; hydroxyl; optionally halogenated (C_1-C_{12})alkyl; optionally halogenated (C_1-C_{12})alkoxy; nitro; cyano; (C_1-C_{12})alkylenedioxy; (C_1-C_{12})alkylene; carboxy(C_1-C_{12})alkyl; (C_2-C_{12})alkenyloxy; optionally halogenated (C_1-C_{12})alkylsulphonyloxy; cyano(C_1-C_{12})-alkyl; -Cy-alk-NH-SO_2-Ar in which alk represents (C_1-C_{12})alkyl, Cy represents (C_3-C_{12})cycloalkyl optionally substituted with one or more substituents Su as defined below and Ar represents (C_6-C_{18})aryl optionally substituted with one or more~~

substituents Su as defined below; -alk-Cy in which alk and Cy are as defined above; (C_1-C_{12})alkoxycarbonyl(C_1-C_{12})alkoxy; (C_1-C_{12})alkoxycarbonyl(C_1-C_{12})alkyl; saturated heterocycle optionally substituted with one or more substituents Su as defined below; (C_1-C_{12})alkylcarbonyloxy; (C_1-C_{12})alkylcarbonylamino; optionally halogenated (C_1-C_{12})alkylthio; (C_1-C_{12})alkylcarbonyloxy(C_1-C_{12})alkoxy; a



group of formula:

in which p = 0, 1, 2, 3 or 4 and in which St is (C_6-C_{18})aryl optionally substituted with one or more substituents Su as defined below; (C_1-C_{12})alkoxycarbonyl; (C_6-C_{18})arylthio optionally substituted with one or more substituents Su as defined below; (C_3-C_{12})cycloalkyl optionally substituted with one or more substituents Su as defined below; -Cy-CO-O-alk in which alk and Cy are as defined above; -alk-Cy-alk'-NH-CO-alk" in which alk and Cy are as defined above, alk' and alk" represent, independently of each other, (C_1-C_{12})alkyl; -NR°-CO-alk'-Het in which alk' is as defined above, R° represents H or (C_1-C_{12})alkyl and Het represents heteroaryl optionally substituted with one or more substituents Su as defined below; di(C_1-C_{12})alkoxyphosphoryl(C_1-C_{12})alkyl; or (C_6-C_{18})aryl optionally substituted with one or more substituents Su as defined below; (C_6-C_{18})aryloxy optionally substituted with one or more substituents Su as defined below; (C_6-C_{18})aryl fused to an unsaturated heterocycle optionally substituted on the heterocycle portion with oxo, the assembly optionally being substituted with one or more substituents Su as defined below; (C_6-C_{18})aryl(C_1-C_{12})alkoxy optionally substituted with one or more substituents Su as defined below; (C_6-C_{18})arylsulphonyl optionally substituted with one or more substituents Su as defined below; (C_6-C_{18})aryl(C_1-C_{12})alkyl in

~~which aryl is optionally substituted with one or more substituents Su as defined below; (C_6-C_{18})arylcarbonyl optionally substituted with one or more substituents Su as defined below; and~~

~~A represents a hydrogen atom, a (C_6-C_{18})aryl group optionally substituted with one or more substituents Su or (C_1-C_{12})alkyl);~~

~~or alternatively~~

R_4 and R_5 together form a group $-CR_6=CR_7-$ in which CR_6 is linked to X; ~~and in which:~~

R_6 represents a hydrogen atom; (C_1-C_{18})alkyl; (C_3-C_{12})cycloalkyl; (C_6-C_{18})aryl; carboxy(C_1-C_{12})alkyl; (C_1-C_{12})alkoxycarbonyl(C_1-C_{12})alkyl; heteroaryl; (C_6-C_{18})aryl(C_1-C_{12})alkyl; or ~~and~~ heteroaryl(C_1-C_{12})alkyl; in which the aryl and heteroaryl portions of these radicals are optionally substituted with (C_1-C_{12})alkyl, (C_1-C_{12})alkoxy, hydroxyl, nitro, halogen or di(C_1-C_{12})alkoxy-phosphoryl(C_1-C_{12})alkyl;

R_7 represents a hydrogen atom; hydroxyl; di(C_1-C_{12})alkylamino(C_1-C_{12})alkyl; optionally halogenated (C_1-C_{18})alkyl; carboxyl; carboxy(C_1-C_{12})alkyl optionally substituted with amino; (C_1-C_{12})alkoxycarbonyl; (C_6-C_{18})aryl; heteroaryl; (C_6-C_{18})aryl(C_1-C_{12})alkyl; ~~or~~ heteroaryl(C_1-C_{12})alkyl; (C_6-C_{18})aryl fused to an unsaturated heterocycle, optionally substituted on the heterocycle portion with oxo; or (C_3-C_{12})cycloalkyl; in which the aryl, heterocycle, cycloalkyl and heteroaryl portions of these radicals are optionally substituted with halogen; hydroxyl; hydroxy(C_1-C_{12})alkoxy; optionally halogenated (C_1-C_{12})alkyl; optionally halogenated (C_1-C_{12})alkoxy; carboxyl; (C_1-C_{12})alkoxycarbonyl; nitro; cyano; cyano(C_1-C_{18})alkyl; (C_1-C_{18})alkylcarbonyloxy; (C_2-C_{12})alkylene; (C_1-C_{12})alkylenedioxy; (C_1-C_{12})alkylthio; (C_6-C_{18})arylthio optionally substituted with one or more substituents Su ~~as~~

~~defined above~~; di(C_1-C_{12})alkylamino; a group of formula:



in which p = 0, 1, 2, 3 or 4 and in which St represents (C_6-C_{18})aryl; -alk-Cy-NH-SO_2-Ar in which alk represents (C_1-C_{12})alkyl, Cy represents (C_3-C_{12})cycloalkyl optionally substituted with one or more substituents Su ~~as defined below~~ and Ar represents (C_6-C_{18})aryl optionally substituted with one or more substituents Su ~~as defined below~~; -Cy-alk-NH-SO_2-Ar ~~in which Cy, alk and Ar are as defined above~~; -alk-Cy ~~in which alk and Cy are as defined above~~; -alk-Cy-alk'-NH-CO-alk" in which ~~alk and Cy are as defined above and~~ alk' and alk" represent, independently, (C_1-C_{12})alkyl; di(C_1-C_{12})alkoxyphosphoryl(C_1-C_{12})alkyl; (C_6-C_{18})aryl optionally substituted with one or more substituents Su ~~as defined below~~; (C_6-C_{18})aryloxy optionally substituted with one or more substituents Su ~~as defined below~~; (C_6-C_{18})arylcarbonyl optionally substituted with one or more substituents Su ~~as defined below~~; (C_6-C_{18})arylsulphonyl optionally substituted with one or more substituents Su ~~as defined below~~; (C_6-C_{18})aryl(C_1-C_{12})alkoxy in which the aryl portion is optionally substituted with one or more substituents Su ~~as defined below~~; saturated heterocycle optionally substituted with one or more substituents Su ~~as defined below~~; (C_6-C_{18})aryl(C_1-C_{12})alkyl optionally substituted with one or more substituents Su ~~as defined below~~;

Su is ~~chosen from~~ hydroxyl, halogen, cyano, nitro, optionally halogenated (C_1-C_{12})alkyl or ~~and~~ optionally halogenated (C_1-C_{12})alkoxy;

or alternatively R_6 and R_7 together form a C_3-C_{12} alkylene chain optionally interrupted with a nitrogen atom which is optionally substituted with (C_1-C_{12})alkyl or

(C_6-C_{18})aryl or (C_6-C_{18})aryl(C_1-C_{12})alkyl, the ring formed by CR_6=CR_7 optionally being fused to (C_6-C_{18})aryl, the ~~(the~~ aryl portions of these radicals optionally being substituted with halogen, nitro, hydroxyl, optionally halogenated (C_1-C_{12})alkyl or optionally halogenated (C_1-C_{12})alkoxy);
or a ~~and the~~ pharmaceutically acceptable ~~salts~~ salt thereof with an acid or base ~~acids or bases~~,
wherein the compounds having the following substituents ~~it being understood that the compounds correspond to one of the definitions (a) to (e) below~~ are excluded: ~~from the context of the invention: (a)~~ X = S; n = 0; R_2 represents methyl and R_3 represents a hydrogen atom; and R_4 and R_5 together form a group -CR_6=CR_7- in which CR_6 is linked to X, R_6 and R_7 together form a -$(CH_2)_3$- or -$(CH_2)_4$- chain or alternatively R_6 represents a hydrogen atom or a propyl group and R_7 is a phenyl group optionally substituted with -OCH_3 or a hydroxyl group~~;~~

~~(b) n = 0 or 2; X = S; R_2 = R_3 = R_4 = H; R_5 = CH_3;~~

~~(c) n = 0; R_2 = H; R_3 = C_6H_5; R_4 = H or CH_3; X = S; R_5 = CH_3;~~

~~(d) n = 0 or 1; R_2 = optionally substituted phenyl; R_3 = R_4 = H; X = NT; T = H or CH_3; R_5 represents optionally substituted benzyl, CH_3 or phenethyl;~~

~~(e) n = 0; R_2 = R_3 = R_4 = H; X = NH; R_5 represents benzyl, phenethyl, hydroxyethyl or 3,4-dimethoxyphenethyl~~.

2. (Currently Amended) ~~Compound~~ A compound according to Claim 1, wherein ~~characterized in that~~ X represents -NT ~~in which T is as defined in Claim 1 and R_4 and R_5 together form -CR_6=CR_7~~.

3. (Currently Amended) ~~Compound~~ A compound according to Claim 1, wherein ~~characterized in that~~ R_3 represents a hydrogen atom.

4. (Currently Amended) ~~Compound~~ A compound

according to Claim 1, wherein ~~characterized in that~~ R_2 represents a hydrogen atom or a (C_6-C_{10})aryl group optionally substituted with halogen, (C_1-C_6)alkoxy, optionally halogenated (C_1-C_6)alkyl, nitro or ~~and~~ hydroxyl.

5. (Currently Amended) ~~Compound~~ A compound according to Claim 1, wherein ~~characterized in that~~ n is 0 or 1 and R_1 represents a halogen atom.

6. (Currently Amended) ~~Compound~~ A compound according to Claim 1, wherein ~~characterized in that~~

X represents S;

~~R_4 represents a hydrogen atom;~~

~~R_5 represents (C_1-C_6)alkyl; hydroxy(C_1-C_6)alkyl; (C_6-C_{10})aryl(C_1-C_6)alkyl; (C_5-C_8)cycloalkenyl(C_1-C_6)alkyl; or isoxazolyl(C_1-C_6)alkyl optionally substituted with one or more (C_1-C_6)alkyls; $-CH_2-CR_a=CR_bR_c$ in which R_a is a hydrogen atom, (C_1-C_6)alkyl or (C_6-C_{10})aryl, R_b is (C_1-C_6)alkyl or a hydrogen atom and R_c represents a hydrogen atom or (C_2-C_{10})alkenyl; a group $-CH_2-CO-Z$ in which Z represents (C_1-C_{10})alkyl, (C_6-C_{10})aryl(C_1-C_6)alkyl, 5- or 6-membered heteroaryl or (C_6-C_{10})aryl optionally fused to a 5- to 7-membered aromatic or unsaturated heterocycle; the aryl and heteroaryl portions of these radicals optionally being substituted with halogen, hydroxyl, (C_1-C_6)alkyl, (C_1-C_6)alkoxy, nitro or (C_6-C_{10})aryl (optionally substituted with halogen, optionally halogenated (C_1-C_6)alkyl, optionally halogenated (C_1-C_6)alkoxy or nitro);~~

~~or alternatively R_4 and R_5 together form a group $-CR_6=CR_7-$ in which~~

R_6 represents a hydrogen atom, (C_1-C_6)alkyl, ~~(C_6-C_{10})aryl (optionally substituted with halogen, hydroxyl, nitro, (C_1-C_6)alkyl or (C_1-C_6)alkoxy),~~ carboxy(C_1-C_6)alkyl, ~~or~~ (C_1-C_6)alkoxycarbonyl(C_1-C_6)alkyl, or (C_6-C_{10})aryl, that is optionally substituted with halogen, hydroxyl, nitro,

(C_1-C_6)alkyl or (C_1-C_6)alkoxy; and

R_7 represents a hydrogen atom; hydroxyl; di(C_1-C_6)alkylamino(C_1-C_6)alkyl; (C_1-C_{10})alkyl; (C_1-C_6)alkoxycarbonyl; (C_6-C_{10})aryl; heteroaryl; (C_6-C_{10})aryl(C_1-C_6)alkyl; the aryl and heteroaryl portions of these radicals optionally being substituted with (C_1-C_6)alkoxycarbonyl, halogen, hydroxyl, (C_1-C_6)alkyl, (C_6-C_{10})aryl, which (C_6-C_{10})aryl ~~(this~~ radical is optionally ~~being~~ substituted with halogen, optionally halogenated (C_1-C_6)alkyl, (C_1-C_6)alkoxy or nitro~~) or (C_6-C_{10})aryl fused to a 5- to 7-membered aromatic or unsaturated heterocycle comprising one, two or three endocyclic hetero atoms chosen from O, N and S~~; or alternatively R_6 and R_7 together form an alkylene chain interrupted with a nitrogen atom optionally substituted with (C_6-C_{10})aryl(C_1-C_6)alkyl in which the aryl portion is optionally substituted with halogen, optionally halogenated (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxyl or nitro.

7. (Currently Amended) ~~Compound~~ A compound according to Claim 1, wherein ~~characterized in that~~ X represents -NT; ~~and R_4 and R_5 together form a group $-CR_6=CR_7-$ in which~~ R_6 represents a hydrogen atom and R_7 represents hydroxyl or (C_6-C_{10})aryl optionally substituted with halogen, nitro, hydroxyl, optionally halogenated (C_1-C_6)alkyl or (C_1-C_6)alkoxy.

8. (Currently Amended) Compound according to Claim 1, which is ~~chosen from:~~

3-(biphenyl-4-yl)-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine;

3-(2-furyl)-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine;

3-[4-(ethoxycarbonyl)phenyl]-5,6-dihydrothiazolo-[2,3-b]-1,3-benzodiazepine;

~~1-(2-furyl)-2-(4,5-dihydro-3*H*-1,3-benzodiazepine-2-~~

~~ylsulphamyl)ethanone;~~

~~1-(biphenyl-4-yl)-2-(4,5-dihydro-3*H*-1,3-benzodiazepine-2-ylsulphamyl)ethanone;~~

3-(biphenyl-3-yl)-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine;

~~1-(3,4-dihydroxyphenyl)-2-(4,5-dihydro-3*H*-1,3-benzodiazepine-2-ylsulphamyl)ethanone;~~

3-(3,4-dihydroxyphenyl)-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine; or ~~and~~

3-(biphenyl-4-yl)-7-chloro-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine.

9-11. (Cancelled)

12. (Currently Amended) ~~Process~~ A process for preparing a compound ~~compounds~~ of formula I according to Claim 1, in which X represents S ~~and R_4 and R_5 together form a group $-CR_6=CR_7-$~~, comprising reacting ~~the reaction of~~ a thione of formula IIa:



IIa

in which n, R_1, R_2 and R_3 are as defined in Claim 1, with an α-halo ketone of formula IVb:

$$R_7\text{-CO-CHR}_6\text{-Hal}^3 \qquad \text{IVb}$$

in which R_6 and R_7 are as defined in Claim 1, and Hal^3 represents a halogen atom,

in a C_2-C_6 aliphatic carboxylic acid, at a temperature of ~~between~~ 90 to ~~and~~ 130°C.

13. (Currently Amended) ~~Process~~ A process according to Claim 12, wherein ~~characterized in that~~ the aliphatic carboxylic acid is acetic acid.

14. (Currently Amended) ~~Process~~ A process according to Claim 12, wherein ~~characterized in that~~ the temperature is maintained at ~~between~~ 100 to ~~and~~ 125°C.

15. (Currently Amended) ~~Process~~ A process for preparing a compound ~~compounds~~ of formula I according to Claim 1, in which X represents -NH, ~~R_4 and R_5 together form a group $-CR_6=CR_7-$~~ and R_7 is not hydroxyl, comprising reacting ~~the reaction of~~ a sulphide of formula V:



V

in which n, R_1, R_2 and R_3 are as defined in Claim 1, ~~R_4 and R_5 together form a $-CR_6=CR_7-$ group~~ and alk represents (C_1-C_6)alkyl, with a protected compound ~~derivative~~ of a the ketone of formula VI:

$$NH_2\text{-}CHR_6\text{-}CO\text{-}R_7 \qquad \text{VI}$$

in which the carbonyl group is protected with a protecting group that is labile in an acidic medium, R_6 and R_7 being as defined in Claim 1, followed by treatment of the resulting compound with an acid.

16. (Currently Amended) ~~Process~~ A process for preparing a compound ~~compounds~~ of formula I according to Claim 1, in which X represents -NT in which T is not a hydrogen atom, ~~R_4 and R_5 together form a group $-CR_6=CR_7$,~~ and R_7 represents hydroxyl, comprising reacting ~~the reaction of~~ a sulphide of formula V:



V

in which n, R_1, R_2 and R_3 are as defined in Claim 1, and alk represents (C_1-C_6)alkyl,
with a compound ~~derivative~~ of formula VIII:

$$HTN-CHR_6-CO-Y \qquad VIII$$

in which T and R_6 are as defined in Claim 1 and Y is a leaving group, at a temperature of ~~between~~ 50 to ~~and~~ 150°C ~~and preferably at a temperature of between 60 and 100°C~~.

17. (Currently Amended) ~~Process~~ A process according to Claim 15, further ~~also~~ comprising reacting ~~the reaction of~~ the compound obtained ~~by carrying out the process of Claim 15,~~ with a halogenated reagent of formula Hal-T in which T represents (C_1-C_6)alkyl, (C_6-C_{10})aryl or (C_6-C_{10})aryl(C_1-C_6)alkyl and Hal is a halogen atom, in the presence of a base, ~~so as~~ to synthesize a ~~the corresponding~~ compound of formula I in which T represents (C_1-C_6)alkyl, (C_6-C_{10})aryl or (C_6-C_{10})aryl(C_1-C_6)alkyl.

18. (Currently Amended) ~~Pharmaceutical~~ A pharmaceutical composition ~~containing an effective amount of at least one~~ comprising a compound of formula (I) according to Claim 1~~, in combination with at least one~~ and a pharmaceutically acceptable vehicle.

19. (Currently Amended) ~~Use of a compound of formula I according to Claim 1, for the preparation of a medicinal product for preventing or~~ A method for treating dyslipidaemia, atherosclerosis or ~~and~~ diabetes or ~~and its~~ complications thereof, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.

20. (Cancelled)

21. (New) A method for treating dyslipidaemia, atherosclerosis or diabetes, comprising administering to a patient in need thereof an effective amount of a compound according to claim 1.

22. (New) A process according to claim 16, wherein the reaction is at a temperature of 60 to 100°C.

23. (New) A compound which is

3-(biphenyl-4-yl)-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine;

3-(2-furyl)-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine;

3-[4-(ethoxycarbonyl)phenyl]-5,6-dihydrothiazolo-[2,3-b]-1,3-benzodiazepine;

1-(2-furyl)-2-(4,5-dihydro-3*H*-1,3-benzodiazepine-2-ylsulphamyl)ethanone;

1-(biphenyl-4-yl)-2-(4,5-dihydro-3*H*-1,3-benzo-

diazepine-2-ylsulphamyl)ethanone;

3-(biphenyl-3-yl)-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine;

1-(3,4-dihydroxyphenyl)-2-(4,5-dihydro-3*H*-1,3-benzodiazepine-2-ylsulphamyl)ethanone;

3-(3,4-dihydroxyphenyl)-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine; or

3-(biphenyl-4-yl)-7-chloro-5,6-dihydrothiazolo[2,3-b]-1,3-benzodiazepine.

24. (New) A method for treating dyslipidaemia, atherosclerosis or diabetes, comprising administering to a patient in need thereof an effective amount of a compound according to claim 23.

25. (New) A compound according to Claim 6, wherein R_6 represents a hydrogen atom, (C_1-C_6)alkyl, carboxy(C_1-C_6)alkyl, or (C_1-C_6)alkoxycarbonyl(C_1-C_6)alkyl.